Table 4.
Univariate and multivariate Cox regression analysis to identify prognostic clinical factors and clinical independence.
| Variables | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | p value | HR | 95% CI of HR | p value | |
| TCGA training datasets | ||||||
| 5-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 2.72 | 2.01-3.66 | 5.310E-11 | 2.27 | 1.30601-3.936 | 0.004 |
| Age | 1.00 | 0.97-1.02 | 9.980E-01 | 1.03 | 0.97001-1.093 | 0.33624 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 0.92 | 0.58-1.43 | 0.70 | 0.63 | 0.30321-1.301 | 0.21085 |
| Smoke years | 0.98 | 0.96-1.01 | 0.37 | 0.99 | 0.96278-1.015 | 0.40262 |
| Pathologic T1 | 1 (reference) | 1 (reference) | ||||
| Pathologic T2 | 1.41 | 0.8314-2.381 | 0.20341 | 1.48 | 0.52948-4.114 | 0.45674 |
| Pathologic T3 | 1.69 | 0.8693-3.283 | 0.122 | 1.74 | 0.2188-13.78 | 0.602 |
| Pathologic T4 | 3.90 | 1.4234-10.69 | 0.008 | 13.87 | 0.25483-754.666 | 0.197 |
| Pathologic N0 | 1 (reference) | 1 (reference) | ||||
| Pathologic N1 | 1.21 | 0.7879-1.857 | 0.384 | 0.54 | 0.10297-2.854 | 0.470 |
| Pathologic N2/N3 | 0.77 | 0.3517-1.686 | 0.513 | 0.91 | 0.02173-37.89 | 0.959 |
| Pathologic M0 | 1 (reference) | 1 (reference) | ||||
| Pathologic M1/MX | 1.70 | 1.059-2.717 | 2.80E-02 | 3.65 | 1.58507-8.395 | 2.34E-03 |
| Tumor stage I | 1 (reference) | 1 (reference) | ||||
| Tumor stage II | 1.02 | 0.6474-1.615 | 0.924 | 1.46 | 0.32211-6.599 | 0.62452 |
| Tumor stage III | 1.27 | 0.7519-2.132 | 0.3749 | 0.89 | 0.0297-26.834 | 0.94791 |
| Tumor stage IV | 3.23 | 0.9983-10.429 | 0.050 | 1.31 | 0.08057-21.187 | 0.85 |
|
| ||||||
| TCGA datasets, GSE42127 | ||||||
| TCGA test datasets | ||||||
| 5-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 1.85 | 1.501-2.283 | 8.89E-09 | 1.737 | 1.2456-2.423 | 1.14E-03 |
| Age | 1.02 | 0.9995-1.033 | 0.058 | 1.029 | 0.9916-1.067 | 0.132 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 1.20 | 0.8669-1.646 | 0.277 | 1.240 | 0.7443-2.067 | 0.408 |
| Smoke years | 0.99 | 0.9739-1.007 | 0.26 | 0.99 | 0.973-1.01 | 0.349 |
| Pathologic T1 | 1 (reference) | 1 (reference) | ||||
| Pathologic T2 | 1.25 | 0.8779-1.765 | 0.219 | 0.89 | 0.4878-1.629 | 0.708 |
| Pathologic T3 | 1.82 | 1.1618-2.847 | 0.009 | 0.897 | 0.27-2.98 | 0.859 |
| Pathologic T4 | 2.32 | 1.2481-4.327 | 0.008 | 1.014 | 0.2338-4.396 | 0.985 |
| Pathologic N0 | 1 (reference) | 1 (reference) | ||||
| Pathologic N1 | 1.07 | 0.7824-1.466 | 0.669 | 0.687 | 0.2744-1.721 | 0.423 |
| Pathologic N2 | 1.32 | 0.831-2.093 | 2.40E-01 | 1.475 | 0.3304-6.588 | 0.611 |
| Pathologic N3 | 2.51 | 0.6183-10.212 | 1.98E-01 | 3.030 | 0.3645-25.18 | 0.305 |
| Pathologic M0 | 1 (reference) | 1 (reference) | ||||
| Pathologic M1 | 3.18 | 1.3-7.778 | 1.13E-02 | 1.472 | 0.1424-15.22 | 0.746 |
| Pathologic MX | 1.55 | 1.049-2.299 | 0.028 | 2.250 | 1.1797-4.293 | 0.014 |
| Tumor stage | 1 (reference) | 1 (reference) | ||||
| Tumor stage II | 1.13 | 0.8234-1.559 | 4.43E-01 | 1.011 | 0.4121-2.48 | 0.981 |
| Tumor stage III | 1.64 | 1.1622-2.311 | 4.84E-03 | 1.351 | 0.2684-6.796 | 0.716 |
|
| ||||||
| GSE42127 | ||||||
| 5-gene risk score | ||||||
| Low risk group | 1 (reference) | 1 (reference) | ||||
| High risk group | 2.07 | 1.133-3.778 | 0.018 | 2.33 | 1.1539-4.697 | 0.018 |
| Age | 1.03 | 0.9751-1.084 | 0.306 | 1.0127 | 0.9497-1.08 | 0.7002 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 1.196 | 0.4723-3.029 | 0.706 | 1.1037 | 0.4032-3.021 | 0.848 |
| Tumor stage I | 1 (reference) | 1 (reference) | ||||
| Tumor stage II | 0.82 | 0.2549-2.643 | 0.741 | 1.00 | 0.2773-3.576 | 0.995 |
| Tumor stage III | 2.0311 | 0.7574-5.447 | 0.159 | 2.7395 | 0.9225-8.136 | 0.070 |